Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study.
Ki-67 index
chromogranin A
gastrin
mitotic count
recurrence
type I gastric neuroendocrine neoplasm
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
09 Mar 2023
09 Mar 2023
Historique:
received:
14
02
2023
revised:
01
03
2023
accepted:
07
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Type I gastric neuroendocrine neoplasms (gNENs) are associated with atrophic gastritis and have a high recurrence rate, which means frequent endoscopies are required. The objective of this study was to identify factors predicting the local recurrence of type I gNENs. The clinical course and the pathological and biochemical data of patients with type I gNENs treated at Bnai Zion Medical Center between 2006 and 2022 were analyzed retrospectively. Twenty-seven type I gNENs were evaluated. The follow-up period was 41 months (range: 11-288 months). Recurrence of the tumor occurred in 13/27 (48%) patients after 35 months (median (M), interquartile range (IQR): 21-67.5). Serum gastrin levels were significantly higher in patients with recurrent disease versus patients with non-recurrent disease (788 vs. 394 ng/L;
Identifiants
pubmed: 36979807
pii: biomedicines11030828
doi: 10.3390/biomedicines11030828
pmc: PMC10045191
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Endocrine. 2016 Jan;51(1):131-9
pubmed: 25814125
Br J Clin Pharmacol. 2017 Mar;83(3):466-475
pubmed: 27704617
Endocr Relat Cancer. 2008 Dec;15(4):1083-97
pubmed: 18603570
Neuroendocrinology. 2012;95(3):207-13
pubmed: 21811050
Am J Gastroenterol. 2010 Dec;105(12):2563-9
pubmed: 20823835
J Gastrointest Surg. 2021 Oct;25(10):2495-2502
pubmed: 33825119
J Clin Med. 2019 Jun 25;8(6):
pubmed: 31242670
World J Gastroenterol. 2013 Dec 14;19(46):8687-95
pubmed: 24379587
World J Gastroenterol. 2019 Sep 21;25(35):5376-5387
pubmed: 31558880
Ann Surg Oncol. 2021 Dec;28(13):8838-8846
pubmed: 34120268
Dig Liver Dis. 2019 Oct;51(10):1456-1460
pubmed: 31175013
Gastric Cancer. 2020 Jul;23(4):591-599
pubmed: 32026156
Histopathology. 2020 Dec;77(6):865-876
pubmed: 32702178
Endocr Relat Cancer. 2010 Oct 05;17(4):909-18
pubmed: 20702725
Cancer. 2008 Jul 15;113(2):256-65
pubmed: 18506737
Neuroendocrinology. 2016;103(2):119-24
pubmed: 26784901
Br J Cancer. 2013 May 14;108(9):1838-45
pubmed: 23579216
Dig Liver Dis. 2022 Jul;54(7):890-895
pubmed: 34903498
Aliment Pharmacol Ther. 2020 Jun;51(12):1247-1267
pubmed: 32390152
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
Clin Endocrinol (Oxf). 2014 Aug;81(2):157-68
pubmed: 24750249
Dig Dis Sci. 2015 Apr;60(4):996-1003
pubmed: 25399327
Clin Endocrinol (Oxf). 2019 Oct;91(4):534-543
pubmed: 31254407
Clin Cancer Res. 2008 Dec 1;14(23):7798-803
pubmed: 19047107
Gastroenterol Clin North Am. 2013 Jun;42(2):381-97
pubmed: 23639647
World J Clin Cases. 2021 Sep 26;9(27):7973-7985
pubmed: 34621854
Eur J Endocrinol. 2013 Jan 17;168(2):185-93
pubmed: 23132699
Sci Rep. 2020 Jul 6;10(1):11064
pubmed: 32632119
Gut. 1998 Aug;43(2):223-8
pubmed: 10189848
Curr Oncol Rep. 2022 Jan;24(1):77-88
pubmed: 35059996